New bone-targeting drug delays onset of metastases in hormone-resistant prostate cancer patients, study finds
Sunday, September 25, 2011 - 20:30
in Health & Medicine
Inhibiting a protein involved in bone metabolism can delay the onset of bone metastases common in men with prostate cancer resistant to hormone treatment. The research on the effects of the monoclonal antibody denosumab is the first large-scale clinical trial to show such an effect. The use of denosumab in this group of patients can impede the onset of bone metastases by just over four months.
